Ontology highlight
ABSTRACT:
SUBMITTER: Denlinger NM
PROVIDER: S-EPMC5877869 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Denlinger Nathan M NM Epperla Narendranath N William Basem M BM
Cancer management and research 20180327
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment ...[more]